Plains All American Pipeline, L.P. (NYSE:PAA)

Plains All American Pipeline, L.P. is engaged in interstate and intrastate marketing, transportation and terminalling of crude oil.

Plains All American Pipeline, L.P. (NYSE:PAA)’s Financial Overview

Plains All American Pipeline, L.P. (NYSE:PAA) surged 11.09% yesterday to close its trading session at $32.95. The company has 1 year Price Target of $31.93. Plains All American Pipeline, L.P. has 52-Week high of $33.27 and 52-Week Low of $14.82. The stock touched its 52-Week High on Nov 30, 2016 and 52-Week Low on Feb 9, 2016. The stock traded with the volume of 7.81 Million shares yesterday. The firm shows the market capitalization of $13.61 Billion.

Plains All American Pipeline, L.P. (NYSE:PAA) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $0.4/share against the analyst consensus estimate of $0.28/share. The difference between the actual and expected EPS is $0.12 a share with a surprise factor of 42.9%.

The firm is trading with SMA20 of 8.22 Percent, SMA50 of 7.47 Percent and SMA200 of 27.58 percent. Plains All American Pipeline, L.P. has P/S value of 0.71 while its P/B value stands at 1.83. Similarly, the company has Return on Assets of 0.9 percent, Return on Equity of 2.8 percent and Return on Investment of 6.1 Percent. The company shows Gross Margin and Operating Margin of 9.7 percent and 5.9 percent respectively.

Many brokerage firms are involved in issuing their ratings on Plains All American Pipeline, L.P. (NYSE:PAA). On 13-Oct-16 Piper Jaffray Upgrade Plains All American Pipeline, L.P. Stock  to Overweight. Another firm also rated the stock on 5-Oct-16 where Wells Fargo Upgrade the stock to Outperform.

The Stock currently has Analyst’ mean Recommendation of 2.3 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 20 analysts offering 12-month price forecasts for Plains All American Pipeline LP have a median target of 32.00, with a high estimate of 37.00 and a low estimate of 26.00. The median estimate represents a -2.88% decrease from the last price of 32.95.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)’s Financial Outlook

The 5 analysts offering 12-month price forecasts for Anthera Pharmaceuticals Inc have a median target of 6.00, with a high estimate of 10.00 and a low estimate of 5.00. The median estimate represents a +300.00% increase from the last price of 1.50.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Anthera Pharmaceuticals, Inc. has a Consensus Recommendation of 1. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock fell -14.77% and closed its last trading session at $1.5. The company has the market capitalization of $62.9 Million. The stock has 52-week high of $5.79 and 52-Week low of $1.47. The firm touched its 52-Week high on Dec 2, 2015 and 52-Week low on Nov 10, 2016. The company has volume of 1.29 Million shares. The company has a total of 41.93 Million shares outstanding.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) in the last quarter reported its actual EPS of $-0.61/share where the analyst estimated EPS was $-0.38/share. The difference between the actual and Estimated EPS is $-0.23. This shows a surprise factor of -60.5 percent.

The company has YTD performance of -67.67 percent. Beta for Anthera Pharmaceuticals, Inc. stands at 1.49 while its ATR (average true range) is 0.18. The company has Weekly Volatility of 7.33%% and Monthly Volatility of 9.28%%.

Anthera Pharmaceuticals, Inc. has distance from 20-day Simple Moving Average (SMA20) of -26.57%, Distance from 50-Day Simple Moving Average of -41.47 percent and Distance from 200-Day Simple Moving Average of -52.98%.

The Company currently has ROA (Return on Assets) of -154.2 percent, Return on Equity (ROE) of -238.2 Percent and Return on Investment (ROI) of -88.8% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.